Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
暂无分享,去创建一个
[1] J. Garcia-conde,et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] G. Sledge. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. , 2001, Oncology.
[3] M. Blackstein,et al. Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II Trial , 2002, Oncology.
[4] A. Murad,et al. Phase II Trial of the Use of Paclitaxel and Gemcitabine as a Salvage Treatment in Metastatic Breast Cancer , 2001, American journal of clinical oncology.
[5] M. Espié,et al. Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast Cancer , 2001, Oncology.
[6] A. Murad,et al. Rationale and dose-finding studies of the combination of irinotecan and a taxane on a weekly schedule. , 2001 .
[7] K. Possinger,et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. , 1999, Anti-cancer drugs.
[8] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[9] L. Einhorn,et al. A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors , 1997 .
[10] A. Harris,et al. Advanced breast cancer: a phase II trial with gemcitabine. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Hudis,et al. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Hudis,et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Hortobagyi,et al. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. , 1993, Journal of the National Cancer Institute. Monographs.